Product Detailed Description

Liposomal urolithin a 70% — High Bioavailability Mitophagy Activator Supplement

Product Overview

liposomal Urolithin A 70% is a premium-grade dietary supplement ingredient delivering urolithin A in an advanced liposomal delivery system. Urolithin A (CAS 1143-70-0), also known as 3,8-dihydroxybenzo[c]chromen-6-one or Uro-A, is a naturally occurring gut microbiota-derived metabolite of ellagitannins and ellagic acid, which are abundant in pomegranates, walnuts, and berries. It is chemically characterized by the molecular formula C₁₃H₈O₄ and a molecular weight of 228.20 g/mol.

Urolithin A exhibits a broad spectrum of biological activities, including antioxidant, anti-inflammatory, and mitochondrial function-enhancing effects, highlighting its potential as a therapeutic agent for various diseases. Preclinical studies have demonstrated that UroA induces mitophagy both in vitro and in vivo, preventing age-associated mitochondrial dysfunction and improving lifespan and muscle function as well as enhancing exercise capacity.

However, its clinical application is limited by poor oral bioavailability and considerable interindividual variability in microbial conversion. Approximately 10% of individuals are classified as urolithin nonproducers, independent of age, posing an additional challenge for clinical translation. Liposomal encapsulation addresses these challenges by bypassing the need for gut microbiota conversion and delivering UroA directly to target tissues.

Why Liposomal Technology?

Conventional urolithin A presents significant formulation challenges. The compound has low water solubility and poor bioavailability, and its clinical translation is hampered by significant inter-individual variability in gut microbiota composition and intestinal absorption, which leads to inconsistent bioconversion and bioavailability of UroA. Approximately 10% of individuals cannot produce urolithin A from dietary precursors at all.

Liposomal encapsulation provides four critical advantages:

1. Bypass of Gut Microbiota Dependency — Liposomal urolithin A is delivered directly to target tissues without requiring gut microbiota conversion, overcoming the variability associated with urolithin metabotypes and ensuring consistent bioavailability across all individuals.

2. Enhanced Bioavailability — Gum arabic-coated urolithin A liposomes (UA-LPs-GA) significantly enhanced the encapsulation efficiency, stability, and bioaccessibility of UroA. Pharmacokinetic studies showed that UA-LPs-GA improved the relative oral bioavailability of UroA by 3.09-fold compared to free UroA. pH-driven liposomal encapsulation demonstrated a 1.91-fold increase in absorption efficiency compared to conventional thin-film methods.

3. Enhanced Stability and Bioaccessibility — Liposomes coated with gum arabic showed the best encapsulation efficiency, bioaccessibility, storage and thermal stability, with bioaccessibility reaching 1.67 times that of uncoated UroA liposomes.

4. Targeted Mitochondrial Delivery — Urolithin A’s primary mechanism of action involves the induction of mitophagy—the selective removal of damaged mitochondria. Liposomal encapsulation facilitates efficient cellular delivery, ensuring UroA reaches the mitochondria of target tissues including skeletal muscle, immune cells, and the brain.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% urolithin A by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation improves relative oral bioavailability by 3.09-fold compared to free UroA, and 1.91-fold compared to conventional liposomal methods.

• Mitophagy Activation — Urolithin A is the first and only known compound clinically validated to stimulate mitophagy in humans, selectively removing damaged mitochondria and maintaining mitochondrial quality control.

• Clinically Validated for Muscle Strength — A systematic review of five studies including 250 healthy individuals demonstrated that UA (10–1,000 mg/day) for 28 days to 4 months increased muscle strength and endurance.

• Clinically Validated for Immune Function — A randomized, double-blind, placebo-controlled trial in 50 healthy middle-aged adults demonstrated that oral UA (1,000 mg/day) for 4 weeks expanded peripheral naive-like CD8⁺ T cells and increased CD8⁺ fatty acid oxidation capacity, supporting its potential to counteract age-related immune decline.

• Mitochondrial Biogenesis Support — UA augmented mitochondrial biogenesis in CD8⁺ cells and increased peripheral NK cells and nonclassical monocytes in clinical trial participants.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have evaluated urolithin A across a range of doses. A systematic review of five studies including 250 healthy individuals used UA at 10–1,000 mg/day for durations ranging from 28 days to 4 months. A randomized, double-blind, placebo-controlled trial in 50 healthy middle-aged adults used 1,000 mg/day for 4 weeks and demonstrated significant immune cell remodeling. An ongoing clinical trial evaluating UA and fisetin for sleep and aging biomarkers uses 500 mg/day for 12 weeks. A placebo-controlled trial in men with prostate cancer undergoing radical prostatectomy uses 1,000 mg/day (two 250 mg capsules BID) for 3–6 weeks. For general mitochondrial health and healthy aging support, 500–1,000 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.